Get the Stockscreener App
64.87
1.01%
0.65
After Hours:
63.11
-1.76
-2.71%
Ani Pharmaceuticals Inc stock is traded at $64.87, with a volume of 453.33K.
It is up +1.01% in the last 24 hours and up +8.13% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$64.22
Open:
$64.22
24h Volume:
453.33K
Relative Volume:
1.91
Market Cap:
$1.34B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
79.11
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+2.55%
1M Performance:
+8.13%
6M Performance:
+7.44%
1Y Performance:
-4.42%
1-Day Range:
$63.25
$65.04
1-Week Range:
$61.37
$65.04
52-Week Range:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
64.87 | 1.34B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - Marketscreener.com
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - The Manila Times
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
ANI Pharma's Strategic $17M Move Boosts Profit Potential for Eye Drug Portfolio - StockTitan
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN
ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha
Exploring Growth Opportunities: Raytheon, ANI Pharmaceuticals, DeckersNews and Statistics - IndexBox, Inc.
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Yahoo Finance
JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World
ANI Pharmaceuticals at Leerink Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks
Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks
Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK
ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Q1 Earnings Estimate for ANIP Issued By HC Wainwright - Defense World
ANI Pharma at Raymond James Conference: Strategic Shift to Rare Diseases - Investing.com Canada
Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific - MSN
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Nasdaq
Rhumbline Advisers Trims Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Principal Financial Group Inc. Acquires 3,816 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to Sell - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at HC Wainwright - Defense World
ANI Pharmaceuticals Reports Record 2024 Results and Raises 2025 Guidance - TipRanks
ANI Pharmaceuticals Gets FDA Approval for Cortrophin Gel in Prefilled Syringe Format as MS Therapy - Marketscreener.com
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ani Pharmaceuticals Inc Stock (ANIP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Davis Krista | SVP, CHIEF HR OFFICER |
Mar 07 '25 |
Sale |
60.86 |
1,000 |
60,860 |
66,525 |
| Gutwerg Ori | SVP, GENERICS |
Mar 05 '25 |
Option Exercise |
31.49 |
300 |
9,447 |
99,476 |
| Gutwerg Ori | SVP, GENERICS |
Mar 05 '25 |
Sale |
60.00 |
5,384 |
323,049 |
94,092 |
| Davis Krista | SVP, CHIEF HR OFFICER |
Feb 21 '25 |
Sale |
60.20 |
1,000 |
60,200 |
68,624 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Feb 13 '25 |
Sale |
59.54 |
400 |
23,816 |
83,478 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Jan 13 '25 |
Sale |
53.92 |
400 |
21,568 |
55,588 |
| CAREY STEPHEN P. | SVP & CFO |
Dec 17 '24 |
Sale |
55.79 |
7,500 |
418,425 |
154,468 |
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):